The Italian market for non-steroids antiinflammatory and antirheumatic medicines is projected to decline gradually from $246.7 million PPP in 2024 to $239.1 million PPP by 2028. This reflects a modest year-on-year decrease of around 1% to 1.5%. In 2023, the sales stood at approximately $248 million PPP, indicating a consistent downward trend. The Compound Annual Growth Rate (CAGR) over the five-year forecast period up to 2028 suggests a mild contraction in market size.
Future trends to watch for include advancements in alternative pain management therapies, potential regulatory changes, and demographic shifts such as Italy's aging population, which could influence demand patterns in this pharmaceutical segment.
